Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Heather, Ziccardi"'
Autor:
Stephen J. Schuster, Alessandra Cesano, Amy Chadburn, John P. Leonard, Heather Ziccardi, William A. Wegener, Scott Z. Fields, David M. Goldenberg, Urte Gayko, Morton Coleman, Michael W. Schuster, Michelle Ashe, Hans J. Hansen, Richard R. Furman, Jamie C. Ketas, Michael Eschenberg, Eric J. Feldman
Publikováno v:
Clinical Cancer Research. 10:5327-5334
Purpose: We conducted a single-center, dose-escalation study evaluating the safety, pharmacokinetics, and efficacy of epratuzumab, an anti-CD22 humanized monoclonal antibody, in patients with aggressive non-Hodgkin’s lymphoma.Experimental Design: E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c1da048c873419297fe8219f2bd9aeb
https://doi.org/10.1158/1078-0432.ccr-04-0294
https://doi.org/10.1158/1078-0432.ccr-04-0294
Autor:
Hans J. Hansen, Heather Ziccardi, Morton Coleman, Alessandra Cesano, Michael Eschenberg, Scott Ely, Jamie C. Ketas, David M. Goldenberg, Amy Chadburn, William A. Wegener, Richard R. Furman, John P. Leonard, Urte Gayko
Publikováno v:
Journal of Clinical Oncology. 21:3051-3059
Purpose: This single-center, dose-escalation study examines the safety, efficacy, and pharmacokinetics of epratuzumab (anti-CD22 humanized monoclonal antibody) in patients with recurrent indolent non-Hodgkin’s lymphoma (NHL).Patients and Methods: P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40ab4a5b102caef093b41f8244e593a0
https://doi.org/10.1200/jco.2003.01.082
https://doi.org/10.1200/jco.2003.01.082
Autor:
John P, Leonard, Morton, Coleman, Jamie C, Ketas, Amy, Chadburn, Richard, Furman, Michael W, Schuster, Eric J, Feldman, Michelle, Ashe, Stephen J, Schuster, William A, Wegener, Hans J, Hansen, Heather, Ziccardi, Michael, Eschenberg, Urte, Gayko, Scott Z, Fields, Alessandra, Cesano, David M, Goldenberg
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 10(16)
We conducted a single-center, dose-escalation study evaluating the safety, pharmacokinetics, and efficacy of epratuzumab, an anti-CD22 humanized monoclonal antibody, in patients with aggressive non-Hodgkin's lymphoma.Epratuzumab was administered once
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5c9ae85932e214428cf2b556f5a32e6c
https://pubmed.ncbi.nlm.nih.gov/15328164
https://pubmed.ncbi.nlm.nih.gov/15328164